## Daniel A Moon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3141031/publications.pdf

Version: 2024-02-01

28 papers 1,072 citations

759055 12 h-index 26 g-index

28 all docs

28 docs citations

28 times ranked

1870 citing authors

#	Article	IF	CITATIONS
1	Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial. European Urology, 2018, 74, 455-462.	0.9	250
2	The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. European Urology, 2021, 80, 682-689.	0.9	181
3	Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. European Urology, 2018, 74, 562-572.	0.9	80
4	Survival and Complications Following Surgery and Radiation for Localized Prostate Cancer: An International Collaborative Review. European Urology, 2018, 73, 11-20.	0.9	76
5	<scp>PADUA</scp> and R.E.N.A.L. nephrometry scores correlate with perioperative outcomes of robotâ€assisted partial nephrectomy: analysis of the Vattikuti Global Quality Initiative in Robotic Urologic Surgery ( <scp>GQI</scp> â€ <scp>RUS</scp> ) database. BJU International, 2017, 119, 456-463.	1.3	75
6	Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma—The RAPPORT Trial. European Urology, 2022, 81, 364-372.	0.9	70
7	Patternsâ€ofâ€care and health economic analysis of robotâ€assisted radical prostatectomy in the Australian public health system. BJU International, 2016, 117, 930-939.	1.3	55
8	Intraductal carcinoma of the prostate can evade androgen deprivation, with emergence of castrateâ€tolerant cells. BJU International, 2018, 121, 971-978.	1.3	39
9	The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. Nature Communications, 2021, 12, 5049.	5.8	33
10	Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy. European Urology Focus, 2021, 7, 234-237.	1.6	31
11	Patients with medical risk factors for chronic kidney disease are at increased risk of renal impairment despite the use of nephron-sparing surgery. BJU International, 2015, 116, 590-595.	1.3	29
12	â€Trifecta' outcomes of robotâ€assisted partial nephrectomy in solitary kidney: a Vattikuti Collective Quality Initiative (VCQI) database analysis. BJU International, 2018, 121, 119-123.	1.3	27
13	Predicting intraâ€operative and postoperative consequential events using machineâ€learning techniques in patients undergoing robotâ€assisted partial nephrectomy: a Vattikuti Collective Quality Initiative database study. BJU International, 2020, 126, 350-358.	1.3	14
14	The Australian laparoscopic non robotic radical prostatectomy experience – analysis of 2943 cases ( <scp>USANZ</scp> supplement). BJU International, 2016, 118, 43-48.	1.3	13
15	Ductal variant prostate carcinoma is associated with a significantly shorter metastasis-free survival. European Journal of Cancer, 2021, 148, 440-450.	1.3	13
16	Comparison of perioperative, renal and oncologic outcomes in roboticâ€essisted versus open partial nephrectomy. ANZ Journal of Surgery, 2018, 88, E194-E199.	0.3	11
17	Changing face of robotâ€assisted radical prostatectomy in Melbourne over 12 years. ANZ Journal of Surgery, 2018, 88, E200-E203.	0.3	11
18	Adverse impact of malnutrition markers on major abdominopelvic cancer surgery. ANZ Journal of Surgery, 2019, 89, 509-514.	0.3	11

#	Article	IF	CITATIONS
19	High prostateâ€specific membrane antigen ( <scp>PSMA) positron emission tomography (PET)</scp> maximum standardized uptake value in men <scp>with Plâ€RADS</scp> score 4 or 5 confers a high probability of significant prostate cancer. BJU International, 2022, 130, 5-7.	1.3	10
20	Developing and evaluating Robocare; an innovative, nurse-led robotic prostatectomy care pathway. European Journal of Oncology Nursing, 2016, 21, 120-125.	0.9	9
21	Omission of Cortical Renorrhaphy During Robotic Partial Nephrectomy: A Vattikuti Collective Quality Initiative Database Analysis. Urology, 2020, 146, 125-132.	0.5	9
22	Cytoreductive surgery for men with metastatic prostate cancer. Prostate International, 2016, 4, 103-106.	1.2	8
23	Outcomes in robotâ€assisted partial nephrectomy for imperative vs elective indications. BJU International, 2021, 128, 30-35.	1.3	7
24	Prostateâ€specific membrane antigen positron emission tomography/computed tomography funding grants free access to superior staging for Australian men with prostate cancer. BJU International, 2022, 130, 8-10.	1.3	6
25	Predictors of erectile dysfunction after transperineal template prostate biopsy. Investigative and Clinical Urology, 2021, 62, 159.	1.0	3
26	Study of the dosimetry, safety, and potential benefit of 177Lu-PSMA-617 radionuclide therapy prior to radical prostatectomy in men with high-risk localized prostate cancer (LuTectomy study) Journal of Clinical Oncology, 2021, 39, TPS264-TPS264.	0.8	1
27	From Novick to the <scp>NHS</scp> : the evolution of minimallyâ€invasive nephronâ€sparing surgery. BJU International, 2017, 120, 458-459.	1.3	0
28	Robotic partial nephrectomy for hilar renal masses. Urology Video Journal, 2022, 13, 100117.	0.1	0